Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC.RCKT · Entity 5627 | See Remarks | May 26, 2026 | May 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ROCKET PHARMACEUTICALS, INC.
Report date May 26, 2026 · Filed May 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.75 · Expires 2028-03-29 | Direct | 0 |
Reported balance
After 2026-05-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-26 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F2: This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock, 3,336 of which will become fully vested and exercisable on March 29, 2019, with the remaining 6,664 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.61 · Expires 2028-06-25 | Direct | 0 |
Reported balance
After 2026-05-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-26 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F3: This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock, 3,336 of which will become fully vested and exercisable on June 25, 2019, with the remaining 6,664 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.56 · Expires 2029-01-28 | Direct | 0 |
Reported balance
After 2026-05-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-26 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F4: This option represents a right to purchase a total of 20,000 shares of the Issuer's Common Stock, 6,672 of which will become fully vested and exercisable on January 28, 2020, with the remaining 13,328 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.85 · Expires 2029-09-02 | Direct | 0 |
Reported balance
After 2026-05-26 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-26 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F5: This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock, 3,336 of which will become fully vested and exercisable on September 2, 2020, with the remaining 6,664 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.72 · Expires 2030-02-06 | Direct | 0 |
Reported balance
After 2026-05-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-26 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F6: This option represents a right to purchase a total of 20,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 6, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.89 · Expires 2030-02-10 | Direct | 0 |
Reported balance
After 2026-05-26 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-05-26 · Disposition to issuer · Disposed 2,000 · Balance 0 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F7: This option represents a right to purchase a total of 2,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 10, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.82 · Expires 2030-08-03 | Direct | 0 |
Reported balance
After 2026-05-26 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-05-26 · Disposition to issuer · Disposed 18,000 · Balance 0 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F8: This option represents a right to purchase a total of 18,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on August 3, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $62.32 · Expires 2031-02-04 | Direct | 0 |
Reported balance
After 2026-05-26 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-05-26 · Disposition to issuer · Disposed 18,000 · Balance 0 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F9: The option represents a right to purchase a total of 18,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 4, 2022, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.05 · Expires 2032-02-14 | Direct | 0 |
Reported balance
After 2026-05-26 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-05-26 · Disposition to issuer · Disposed 27,003 · Balance 0 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F10: This option represents a right to purchase a total of 27,003 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.12 · Expires 2032-04-18 | Direct | 0 |
Reported balance
After 2026-05-26 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-05-26 · Disposition to issuer · Disposed 28,910 · Balance 0 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F11: This option represents a right to purchase a total of 28,910 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on April 18, 2023, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.04 · Expires 2033-02-14 | Direct | 0 |
Reported balance
After 2026-05-26 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-05-26 · Disposition to issuer · Disposed 49,798 · Balance 0 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F12: This option represents a right to purchase a total of 49,798 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.01 · Expires 2034-02-16 | Direct | 0 |
Reported balance
After 2026-05-26 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-05-26 · Disposition to issuer · Disposed 24,545 · Balance 0 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F13: This option represents a right to purchase a total of 24,545 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 16, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2031-05-26 | Direct | 51,509 |
Reported balance
After 2026-05-26 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-05-26 · Grant · Acquired 51,509 · Balance 51,509 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F14: Represents a right to purchase shares of the Issuer's common stock, which will become fully vested on May 26, 2027, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2032-02-14 | Direct | 15,002 |
Reported balance
After 2026-05-26 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-05-26 · Grant · Acquired 15,002 · Balance 15,002 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F14: Represents a right to purchase shares of the Issuer's common stock, which will become fully vested on May 26, 2027, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2032-04-18 | Direct | 16,061 |
Reported balance
After 2026-05-26 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-05-26 · Grant · Acquired 16,061 · Balance 16,061 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F14: Represents a right to purchase shares of the Issuer's common stock, which will become fully vested on May 26, 2027, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2033-02-14 | Direct | 24,899 |
Reported balance
After 2026-05-26 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-05-26 · Grant · Acquired 24,899 · Balance 24,899 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F14: Represents a right to purchase shares of the Issuer's common stock, which will become fully vested on May 26, 2027, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2034-02-16 | Direct | 9,091 |
Reported balance
After 2026-05-26 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-05-26 · Grant · Acquired 9,091 · Balance 9,091 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F15: This option represents a right to purchase a total of 9,091 shares of the Issuer's common stock, one-half of which will become fully vested and exercisable on May 26, 2027, with the remaining shares becoming fully vested and exercisable on May 26, 2028, in each case, subject to the reporting person's continued employment with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026.
F2: This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock, 3,336 of which will become fully vested and exercisable on March 29, 2019, with the remaining 6,664 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
F3: This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock, 3,336 of which will become fully vested and exercisable on June 25, 2019, with the remaining 6,664 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
F4: This option represents a right to purchase a total of 20,000 shares of the Issuer's Common Stock, 6,672 of which will become fully vested and exercisable on January 28, 2020, with the remaining 13,328 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
F5: This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock, 3,336 of which will become fully vested and exercisable on September 2, 2020, with the remaining 6,664 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
F6: This option represents a right to purchase a total of 20,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 6, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
F7: This option represents a right to purchase a total of 2,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 10, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
F8: This option represents a right to purchase a total of 18,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on August 3, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
F9: The option represents a right to purchase a total of 18,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 4, 2022, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
F10: This option represents a right to purchase a total of 27,003 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
F11: This option represents a right to purchase a total of 28,910 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on April 18, 2023, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
F12: This option represents a right to purchase a total of 49,798 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
F13: This option represents a right to purchase a total of 24,545 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 16, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
F14: Represents a right to purchase shares of the Issuer's common stock, which will become fully vested on May 26, 2027, subject to the reporting person's continued employment with the Issuer.
F15: This option represents a right to purchase a total of 9,091 shares of the Issuer's common stock, one-half of which will become fully vested and exercisable on May 26, 2027, with the remaining shares becoming fully vested and exercisable on May 26, 2028, in each case, subject to the reporting person's continued employment with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2024 Filed Feb 22, 2024 01:54 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock | 8,322 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-008888 · form4.xml · nonDerivative · entry 2 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,517 F1 · security: The shares beneficially owned by the reporting person are subject to a lock-up agreement dated September 12, 2023 (the "Lock-Up Agreement"). F4 · security: Represent RSUs that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on February 16, 2025, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 01:54 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 3,238 | $29.84 | $96,615.44 |
DisclosureSEC source: 0001140361-24-008888 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,195 F1 · security: The shares beneficially owned by the reporting person are subject to a lock-up agreement dated September 12, 2023 (the "Lock-Up Agreement"). F2 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person. F3 · shares: The shares of common stock were sold by the Reporting Person pursuant to an exemption to the Lock-Up Agreement in order to pay tax withholding obligations in connection with the vesting of RSUs. Notwithstanding the sales reported on this Form 4, the securities beneficially owned by the reporting person remain subject to the terms of the Lock-Up Agreement. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 5,549 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-008357 · form4.xml · derivative · entry 3 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,159 Underlying: Common Stock · 5,549 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. F4 · derivative.expiration_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 725 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-008357 · form4.xml · derivative · entry 2 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,903 Underlying: Common Stock · 725 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. F3 · derivative.expiration_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 6,274 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-008357 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. F1 · shares: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. Read SEC document |
| January 22, 2024 Filed Jan 23, 2024 21:22 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 638 | $27.20 | $17,355.51 |
DisclosureSEC source: 0001140361-24-003421 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,159 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person. F2 · kind: The shares of common stock were sold by the Reporting Person pursuant to an exemption to the Lock-Up Agreement in order to pay tax withholding obligations in connection with the vesting of RSUs. Notwithstanding the sales reported on this Form 4, the securities beneficially owned by the reporting person remain subject to the terms of the Lock-Up Agreement. Read SEC document |
| January 18, 2024 Filed Jan 22, 2024 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 1,586 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-003111 · form4.xml · derivative · entry 2 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,932 Underlying: Common Stock · 1,586 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: One-third (1/3) of such RSUs became fully vested and exercisable on April 18, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. F3 · derivative.expiration_date: One-third (1/3) of such RSUs became fully vested and exercisable on April 18, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| January 18, 2024 Filed Jan 22, 2024 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 1,586 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-003111 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. F1 · shares: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 23:58 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 725 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-053705 · form4.xml · derivative · entry 2 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,628 Underlying: Common Stock · 725 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. F3 · derivative.expiration_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 23:58 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 725 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-053705 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. F1 · shares: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. Read SEC document |
| October 20, 2023 Filed Oct 25, 2023 13:38 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 564 | $17.06 | $9,622.97 |
DisclosureSEC source: 0001140361-23-049426 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,760 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person. F2 · kind: The shares of common stock were sold by the Reporting Person pursuant to an exemption to the Lock-Up Agreement in order to pay tax withholding obligations in connection with the vesting of RSUs. Notwithstanding the sales reported on this Form 4, the securities beneficially owned by the reporting person remain subject to the terms of the Lock-Up Agreement. Read SEC document |
| October 18, 2023 Filed Oct 20, 2023 22:37 UTC Amendment | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 1,586 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-049079 · form4.xml · derivative · entry 3 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,518 Underlying: Common Stock · 1,586 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: One-third (1/3) of such RSUs became fully vested and exercisable on April 18, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. F6 · derivative.expiration_date: One-third (1/3) of such RSUs became fully vested and exercisable on April 18, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| October 18, 2023 Filed Oct 20, 2023 22:37 UTC Amendment | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 1,586 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-049079 · form4.xml · nonDerivative · entry 2 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Represents shares of Common Stock received upon vesting of an RSU award. F4 · shares: Represents shares of Common Stock received upon vesting of an RSU award. F2 · balance_after: The error in the original Form 4 was carried through in Column 5 of Table 1 in subsequent filings but is corrected in the total amount of securities owned in this Form 4. Read SEC document |
| August 17, 2023 Filed Aug 21, 2023 20:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 284 | $15.47 | $4,393.76 |
DisclosureSEC source: 0001140361-23-040693 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,570 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person. Read SEC document |
| August 14, 2023 Filed Aug 15, 2023 20:17 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 725 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-039905 · form4.xml · derivative · entry 2 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,353 Underlying: Common Stock · 725 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. F3 · derivative.expiration_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| August 14, 2023 Filed Aug 15, 2023 20:17 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 725 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-039905 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. F1 · shares: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. Read SEC document |
| July 20, 2023 Filed Jul 24, 2023 20:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 573 | $19.03 | $10,905.91 |
DisclosureSEC source: 0001140361-23-035859 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,129 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 1,586 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-035428 · form4.xml · derivative · entry 2 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,104 Underlying: Common Stock · 1,586 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: One-third (1/3) of such RSUs became fully vested and exercisable on April 18, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. F3 · derivative.expiration_date: One-third (1/3) of such RSUs became fully vested and exercisable on April 18, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 1,586 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-035428 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. F1 · shares: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 245 | $21.38 | $5,236.88 |
DisclosureSEC source: 0001140361-23-025741 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,116 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person. Read SEC document |
| May 14, 2023 Filed May 17, 2023 00:01 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 725 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-025132 · form4.xml · derivative · entry 2 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,078 Underlying: Common Stock · 725 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. F3 · derivative.expiration_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| May 14, 2023 Filed May 17, 2023 00:01 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 725 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-025132 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. F1 · shares: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. Read SEC document |
| April 21, 2023 Filed Apr 25, 2023 22:33 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 2,342 | $18.65 | $43,678.30 |
DisclosureSEC source: 0001140361-23-020312 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,636 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs received by the Reporting Person. F2 · price: This transaction was executed in multiple brokered trades at prices ranging from $18.55 to $18.88. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 18, 2023 Filed Apr 20, 2023 22:34 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 6,364 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-019447 · form4.xml · derivative · entry 2 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,670 Underlying: Common Stock · 6,364 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: One-third (1/3) of such RSUs became fully vested and exercisable on April 18, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. F3 · derivative.expiration_date: One-third (1/3) of such RSUs became fully vested and exercisable on April 18, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| April 18, 2023 Filed Apr 20, 2023 22:34 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 6,364 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-019447 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,978 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. F1 · shares: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 00:28 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 1,244 | $19.06 | $23,710.64 |
DisclosureSEC source: 0001140361-23-008103 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,614 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person. F2 · price: This transaction was executed in multiple brokered trades at prices ranging from $18.735 to $19.195. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 17, 2023 Filed Oct 20, 2023 22:37 UTC Amendment | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 1,076 | $19.06 | $20,508.56 |
DisclosureSEC source: 0001140361-23-049079 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,782 F1 · security: This Form 4 corrects an error on the original Form 4 filed on February 22, 2023. The original Form 4 stated that the Reporting Person sold 1,244 shares of the Issuer's common stock to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person. The Reporting Person sold 1,076 shares of the Issuer's common stock on February 17, 2023 to cover tax withholding obligations in connection with the vesting of RSUs. F1 · shares: This Form 4 corrects an error on the original Form 4 filed on February 22, 2023. The original Form 4 stated that the Reporting Person sold 1,244 shares of the Issuer's common stock to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person. The Reporting Person sold 1,076 shares of the Issuer's common stock on February 17, 2023 to cover tax withholding obligations in connection with the vesting of RSUs. F3 · price: This transaction was executed in multiple brokered trades at prices ranging from $18.735 to $19.195. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: The error in the original Form 4 was carried through in Column 5 of Table 1 in subsequent filings but is corrected in the total amount of securities owned in this Form 4. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:45 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantRestricted Stock Units · Derivative | 16,616 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-007485 · form4.xml · derivative · entry 2 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,616 Underlying: Common Stock · 16,616 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. F3 · derivative.expiration_date: One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:45 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 49,798 | $0.00 Strike: $20.04 | $0.00 |
DisclosureSEC source: 0001140361-23-007485 · form4.xml · derivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,798 Underlying: Common Stock · 49,798 shares Expires 2033-02-13 F1 · derivative.exercise_date: This option represents a right to purchase a total of 49,798 shares of the Issuer's common stock, one-third (1/3) of which will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2023 Filed Feb 23, 2023 00:25 UTC Amendment | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 2,858 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-008099 · form4.xml · derivative · entry 4 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,803 Underlying: Common Stock · 2,858 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The original Form 4, filed on February 16, 2023, is being amended by this amendment to include the vesting of restricted stock units that took place on February 14, 2023. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: One-third (1/3) of such restricted stock units became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. F6 · derivative.expiration_date: One-third (1/3) of such restricted stock units became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2023 Filed Feb 23, 2023 00:25 UTC Amendment | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantRestricted Stock Units · Derivative | 16,616 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-008099 · form4.xml · derivative · entry 3 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,616 Underlying: Common Stock · 16,616 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. F5 · derivative.expiration_date: One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2023 Filed Feb 23, 2023 00:25 UTC Amendment | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 49,798 | $0.00 Strike: $20.04 | $0.00 |
DisclosureSEC source: 0001140361-23-008099 · form4.xml · derivative · entry 2 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,798 Underlying: Common Stock · 49,798 shares Expires 2033-02-13 F3 · derivative.exercise_date: This option represents a right to purchase a total of 49,798 shares of the Issuer's common stock, one-third (1/3) of which will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2023 Filed Feb 23, 2023 00:25 UTC Amendment | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 2,858 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-008099 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,858 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The original Form 4, filed on February 16, 2023, is being amended by this amendment to include the vesting of restricted stock units that took place on February 14, 2023. F2 · shares: Represents shares of Common Stock received upon vesting of a restricted stock unit award. Read SEC document |
| February 14, 2023 Filed Mar 26, 2024 00:54 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | OtherRestricted Stock Units · Derivative | 11,067 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-015101 · form4.xml · derivative · entry 9 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,903 shares Expires not disclosed F1 · security: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F2 · security: One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F1 · kind: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F1 · derivative.exercise_date: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F1 · derivative.expiration_date: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. Read SEC document |
| February 14, 2023 Filed Mar 26, 2024 00:54 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | OtherCommon Stock | 11,067 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-015101 · form4.xml · nonDerivative · entry 4 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,729 F1 · security: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F2 · security: One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. F1 · kind: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 21:27 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantRestricted Stock Units · Derivative | 14,310 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-029890 · form4.xml · derivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,310 Underlying: Common Stock · 14,310 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units will become fully vested on August 12, 2025. F2 · derivative.expiration_date: The restricted stock units will become fully vested on August 12, 2025. Read SEC document |
| August 12, 2022 Filed Mar 26, 2024 00:54 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | OtherRestricted Stock Units · Derivative | 14,310 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-015101 · form4.xml · derivative · entry 8 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,310 shares Expires not disclosed F1 · security: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F3 · security: Vests in full on August 12, 2025. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F1 · kind: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F1 · derivative.exercise_date: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F1 · derivative.expiration_date: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. Read SEC document |
| August 12, 2022 Filed Mar 26, 2024 00:54 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | OtherCommon Stock | 14,310 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-015101 · form4.xml · nonDerivative · entry 3 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,662 F1 · security: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F3 · security: Vests in full on August 12, 2025. F1 · kind: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 20:06 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantRestricted Stock Units · Derivative | 19,054 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-015162 · form4.xml · derivative · entry 2 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,054 Underlying: Common Stock · 19,054 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: One-third (1/3) of such restricted stock units will become fully vested and exercisable on April 18, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. F3 · derivative.expiration_date: One-third (1/3) of such restricted stock units will become fully vested and exercisable on April 18, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 20:06 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 28,910 | $0.00 Strike: $13.12 | $0.00 |
DisclosureSEC source: 0001140361-22-015162 · form4.xml · derivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,910 Underlying: Common Stock · 28,910 shares Expires 2032-04-17 F1 · derivative.exercise_date: This option represents a right to purchase a total of 28,910 shares of the Issuer's common stock, one-third (1/3) of which will become fully vested and exercisable on April 18, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| April 18, 2022 Filed Mar 26, 2024 00:54 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | OtherRestricted Stock Units · Derivative | 7,932 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-015101 · form4.xml · derivative · entry 7 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,932 shares Expires not disclosed F1 · security: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F2 · security: One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F1 · kind: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F1 · derivative.exercise_date: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F1 · derivative.expiration_date: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. Read SEC document |
| April 18, 2022 Filed Mar 26, 2024 00:54 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | OtherCommon Stock | 7,932 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-015101 · form4.xml · nonDerivative · entry 2 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,352 F1 · security: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F2 · security: One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. F1 · kind: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 02:02 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantRestricted Stock Units · Derivative | 8,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-005824 · form4.xml · derivative · entry 2 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,661 Underlying: Common Stock · 8,661 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. F3 · derivative.expiration_date: One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 02:02 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 27,003 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001140361-22-005824 · form4.xml · derivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,003 Underlying: Common Stock · 27,003 shares Expires 2032-02-13 F1 · derivative.exercise_date: This option represents a right to purchase a total of 27,003 shares of the Issuer's common stock, one-third (1/3) of which will become fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2022 Filed Mar 26, 2024 00:54 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | OtherRestricted Stock Units · Derivative | 2,903 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-015101 · form4.xml · derivative · entry 6 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,903 shares Expires not disclosed F1 · security: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F2 · security: One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F1 · kind: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F1 · derivative.exercise_date: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F1 · derivative.expiration_date: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. Read SEC document |
| February 14, 2022 Filed Mar 26, 2024 00:54 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | OtherCommon Stock | 2,903 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-015101 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,420 F1 · security: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F2 · security: One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. F1 · kind: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. Read SEC document |
| February 04, 2021 Filed Feb 9, 2021 01:44 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Disposition to issuerStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $62.32 | $0.00 |
DisclosureSEC source: 0001140361-21-003784 · form4.xml · derivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2031-02-03 F1 · derivative.exercise_date: The option represents a right to purchase a total of 18,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 4, 2022, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| August 03, 2020 Filed Aug 6, 2020 00:55 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $24.82 | $0.00 |
DisclosureSEC source: 0001140361-20-017591 · form4.xml · derivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2030-08-03 F1 · derivative.exercise_date: This option represents a right to purchase a total of 18,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on August 3, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| February 10, 2020 Filed Feb 10, 2020 22:06 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $23.89 | $0.00 |
DisclosureSEC source: 0001209191-20-008012 · doc4.xml · derivative · entry 2 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2030-02-10 F2 · derivative.exercise_date: This option represents a right to purchase a total of 2,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 10, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 22:06 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $22.72 | $0.00 |
DisclosureSEC source: 0001209191-20-008012 · doc4.xml · derivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-02-06 F1 · derivative.exercise_date: This option represents a right to purchase a total of 20,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 6, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.